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Objective: The influence of operator-dependent variables on the outcomes of lower extremity bypass (LEB) surgery have
primarily been reported in single-institution, retrospective studies. We utilized data from a prospective, multicenter trial
to identify technical variables that were significantly associated with early and midterm results of autogenous LEB for
limb salvage.
Methods: The PREVENT III trial database includes 1404 North American patients with critical limb ischemia (CLI) who
underwent LEB using excised autogenous vein. The study protocol excluded claudicants and in situ reconstructions.
Technical factors analyzed included vein diameter, conduit type, graft length, vein orientation, location of proximal and
distal anastomoses, and performance of completion imaging. Univariate analysis was used to determine the effect of these
factors on 30 day and 1-year outcomes. Multivariate Cox regression models evaluated the influence of these factors while
adjusting for age, sex, race, tobacco, diabetes, dialysis-dependency, previous index limb bypass, and study drug
(edifoligide) administration. The primary outcomes were primary patency (PP), primary assisted patency (PAP), and
secondary patency (SP) assessed by Kaplan-Meier method.
Results: Univariate analysis revealed that vein diameter <3.5 mm and composite graft type were significantly associated
with early (30 day) graft failure. At 1 year, multivariate analysis revealed that patency rates were negatively associated with
diameter <3.5 mm (PP, PAP, SP), non-great saphenous vein (GSV) type (PP, SP), and graft lengths >50 cm (PP only).
Limb salvage and survival at 1 year were not significantly impacted by technical variables. Employing a prespecified trial
definition of high-risk conduits (diameter <3mm or nonsingle segment GSV; 24% of entire cohort) revealed that use of
such conduits was associated with a 2.1-fold increased risk of 30 day graft failure (P < .05), as well as reduced PP, PAP,
and SP at 1 year. Use of a high-risk conduit was also associated with an increased index length of stay (mean 9.37 vs 8.71
days, P  .03) and a greater number of reinterventions (mean 0.67 vs 0.42, P < .0001) over the ensuing year.
Conclusions: In this large, multicenter cohort of patients undergoing LEB for CLI, vein diameter and conduit type were
the dominant technical determinants of early and late graft failure. High-risk conduits and longer grafts may benefit from
aggressive postoperative graft surveillance. ( J Vasc Surg 2007;46:1180-90.)The use of an autogenous vein to bypass a diseased
artery in order to restore distal circulation was first reported
in 1951 by Kunlin.1 Since this landmark paper, the superi-
ority of autogenous vein over prosthetic and endovascular
options has persisted as the most flexible and durable
method for lower extremity revascularization, particularly
in the setting of limb salvage. Nonetheless, despite im-
proved surgical techniques and careful postoperative sur-
veillance, bypass grafts continue to fail, often with severe
consequences for the affected patient. Primary, primary
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1180assisted, and secondary patency rates from the recent and
largest multicenter trial conducted of patients undergoing
infrainguinal bypass were reported as 61%, 77%, and 80% at
1 year.2
Although many published studies have addressed as-
pects of surgical technique in relation to lower extremity
bypass outcomes, the exact contribution of specific techni-
cal factors, some of which may be under the control of the
operating surgeon, remains somewhat uncertain. Classical
teaching considers early (30-day) graft failure to be primar-
ily “technical” in nature, however, conduit type and quality
are known to impact on long term graft patency. Numerous
single-institution retrospective studies have reported the
effects of individual vein characteristics such as conduit
diameter,3,4 graft type,5-11 vein length,12 conduit orienta-
tion,13 location of proximal14,15 and distal anastomoses,16
and performance of completion imaging,17-19 Two pro-
spective randomized studies of infrainguinal bypass graft-
ing have been carried out to examine the effect of a specific
technical variable (proximal anastomosis site,12 vein orien-
tation20) on infrainguinal bypass outcomes. However,
these single center studies may be limited by the selection
biases of the individual surgeons, as preferred strategies for
anastomotic sites, conduit selection, vein preparation, graft
orientation, and postoperative surveillance are variable and
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studies may not be directly applicable outside of the center
of origin.
This study has sought to address this topic by utiliz-
ing the Project of Ex Vivo graft Engineering via Trans-
fection III (PREVENT III) database.2 PREVENT III
was a prospective, randomized, double-blinded, multi-
center trial designed to examine a novel pharmacologic
agent’s (edifoligide) efficacy to prevent autogenous vein
graft failure in patients who underwent infrainguinal
bypass (IB) exclusively for the treatment of critical limb
ischemia (CLI). The objective of this study was to utilize
this unique database to assess the influence of specific
technical factors on early (30 day) and midterm (1 year)
outcomes of autogenous vein IB.
PATIENTS AND METHODS
The PREVENT III cohort. The PREVENT III
study was a phase III multicenter, randomized, double-
blinded, placebo-controlled trial of edifoligide for preven-
tion of vein graft failure in patients who underwent IB for
CLI. Details of the trial design have been described else-
where21 and only relevant features are briefly reviewed
here. Edifoligide is a short (14 base pair) double-stranded
DNA molecule that inhibits cell cycle gene expression and
was hypothesized to reduce neonintimal hyperplasia. How-
ever, in the primary PREVENT III analysis,2 the treatment
of vein grafts with edifoligide was found to confer no
benefit on the prespecified primary and secondary end-
points. The study cohort consisted of 1404 patients with
CLI drawn from 83 community and university hospitals
located across Canada and theUnited States. The study was
Table I. Patient characteristics in the PREVENT III
cohort
Number (%)
Patients 1404
Age (mean  SD) 69  12 y
Female gender 507 (36.1)
Race/ethnicity
Caucasian 1017 (72.4)
African-American 249 (17.7)
Other 138 (9.8)
Risk factors for PVD
Smoking 1036 (73.8)
Diabetes mellitus 900 (64.1)
Hypertension 1146 (81.6)
Coronary artery disease 586 (41.7)
Prior CABG 349 (24.9)
Dialysis-dependent renal failure 170 (12.1)
Prior infrainguinal bypass graft
(either extremity) 383 (27.3)
CLI criterion (most severe)
Rest pain 353 (25.1)
Nonhealing ulcer 553 (39.4)
Gangrene 493 (35.1)
PVD, Peripheral vascular disease; CABG, coronary artery bypass graft; CLI,
critical limb ischemia.independently reviewed and approved by the institutionalreview boards at all participating institutions. General charac-
teristics of the study population are summarized in Table I,
and additional detailed information may be found in the
primary trial report.2 The inclusion criteria specified pa-
tients at least 18 years of age who underwent IB with
autogenous vein for CLI (defined as gangrene, a nonheal-
ing ischemic ulcer, or ischemic rest pain). Exclusion criteria
included in situ reconstructions (the protocol required that
the vein be excised to be treated with study drug ex vivo)
and claudication as an indication for IB surgery.
Demographic variables as well as a detailed vascular
exam were collected prior to surgery as part of a compre-
hensive history and physical exam. Protocol-specific tech-
nical variables related to the surgery were recorded at the
time of bypass by the operating surgeon. These variables
included, but were not limited to: conduit diameter (as
measured at the narrowest point on distension), graft type
(great saphenous vein [GSV], small saphenous vein [SSV],
arm vein [ARM], composite [ie, spliced vein as opposed to
single-segment grafts]), vein length, bypass configuration
(site of proximal anastomosis, site of distal anastomosis),
conduit orientation (reversed, nonreversed), and the per-
formance of a completion imaging study (duplex ultra-
sound or angiogram). The study protocol also prespecified
a definition for “high-risk” grafts as including any vein with
a diameter 3 mm or any nonsingle segment (SS) GSV
conduit. This was done to specifically test the hypothesis
that edifoligide would be efficacious in high-risk conduits,
as a planned secondary endpoint. Investigators were al-
lowed to use any medication before and after the surgery
that was consistent with their usual clinical practice pattern.
However, the use of postoperative anticoagulants exclu-
sively for the prevention of bypass graft occlusion was
specifically discouraged by the protocol.
The study subjects were followed for 1 year from the
time of surgery with postoperative graft ultrasound surveil-
lance performed at 1, 3, 6, and 12 months after bypass
surgery and physical examination, including an ABI, per-
formed at 1, 3, 6, 9, and 12 months post surgery. A clinical
events classification committee performed a blinded,
independent review of each case of index graft failure. A
total of 44 patients (3.2%) either withdrew or were lost
to follow-up in PREVENT III.
Study design. The cohort was analyzed in order to
determine the effect of each individual technical factor on
early outcomes (within 30 days) and midterm outcomes
(within 1 year). Technical variables analyzed included vein
diameter (3 mm, 3 mm to 3.49 mm,3.5 mm), conduit
type (composite, SSV or arm vein, SS GSV), graft length
(40 cm, 40 to 50 cm, 51 to 60 cm, 60 cm), vein
orientation (reversed, nonreversed), location of proximal
(common femoral artery [CFA], superficial femoral artery
[SFA], popliteal) and distal anastomoses (popliteal, tibial,
pedal), and performance of completion imaging (duplex or
angiogram). The primary endpoints were primary patency
(PP), primary assisted patency (PAP), and secondary pa-
tency (SP). Secondary endpoints included limb salvage
(LS) and death. All endpoints were defined in accordance
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extremity revascularization22 and assessed by Kaplan-Meier
method. The unadjusted (univariate) effect of each individual
technical variable on the primary and secondary outcomes
were studied at both 30 days and 1 year. Multivariate models
evaluated the influence of each of the factors found to be
significant on univariate analysis at 1 year while adjusting for
age, sex, race, tobacco, diabetes, dialysis-dependency, previ-
ous index limb bypass, statin use, antiplatelet use, and study
drug (edifoligide) administration. Of note, multivariate mod-
eling of 30 day outcomes was not possible due to the paucity
of events at the early time point. Resource utilization measures
included index length of stay (LOS) as well as the number of
reinterventions, rehospitalizations, and cumulative LOS over
the 1-year follow-up period.
Statistical analysis. Differences in PP, PAP, SP, LS,
and survival were compared by category for each technical
variable at 30 days and at 1 year. Univariate comparisons at
30 days were made using Fischer exact test. Time-to-event
Table II. Univariate analysis of the effect of technical fact
surgery
N PP % PA
All conduits 1404 91.0 9
Graft diameter
3 mm 77 85.7 8
3 to 3.5 mm 523 89.7 9
3.5 mm 701 93.2 9
P  .007 P 
Graft length
40 cm 438 93.2 9
40 to50 cm 345 91.3 9
50 to 60 cm 217 87.6 9
60 cm 353 90.1 9
P  .112 P 
Graft Type
GSV-SS 1086 92.2 9
SSV or ARM 66 92.4 9
Composite 201 84.1 9
P  .001 P 
Orientation*
Reversed 385 93.3 9
Nonreversed 701 91.6 9
P  .329 P 
Origin
CFA 665 91.7 9
SFA 334 87.7 9
Pop 229 93.9 9
P  .028 P 
Distal
Pop 443 90.3 9
Tibial 719 91.5 9
Pedal 160 89.4 9
P  .617 P 
Completion study
Yes 788 91.4 9
No 616 90.7 9
P  .674 P 
PP, Primary patency; PAP, primary assisted patency; SP, secondary patency;
or arm vein.
*Orientation refers to SS-GSV grafts only.endpoint analyses at 1 year were performed using theKaplan-Meier method and the treatment groups were com-
pared by using the log rank test. All technical variables that
were found to be significant (P  .05) on univariate analysis
were then introduced into multivariate Cox proportional
hazards models in order to identify independent predictors.
Comparisons of the number of reinterventions, number of
rehospitalizations, index LOS, and cumulative LOS were
made withWilcoxon rank sum tests for nonparametric data.
All tests were considered statistically significant at an alpha
level of 0.05 (P  .05). All analyses were performed using
SAS version 9.1 (Cary, NC).
RESULTS
Early (30-day) graft failure. For the 1404 patients in
the entire study cohort, there was a 9.0% loss of primary
patency and a 3.9% loss of secondary patency within 30
days. In the univariate analysis, significant technical pre-
dictors of early loss of PP included small conduit diam-
eter (P  .007), composite vein type (P  .001), and
n early (30 day) outcomes after lower extremity bypass
SP % Limb salvage % Survival %
96.1 98.2 97.4
89.6 96.2 94.1
95.2 98.5 97.1
97.4 98.2 97.9
P  .002 P  .381 P  .110
95.7 98.9 98.0
96.8 98.6 95.6
94.0 96.8 98.2
97.2 97.8 97.8
P  .237 P  .255 P  .110
96.8 98.4 97.2
93.9 95.5 97.1
93.0 97.5 98.0
P  .028 P  .166 P  .798
98.4 98.7 97.2
95.9 98.3 97.3
P  .022 P  .603 P  .987
96.8 98.1 98.0
94.6 98.2 96.5
96.5 97.8 97.5
P  .209 P  .954 P  .389
96.2 99.1 97.4
96.4 97.8 97.5
93.8 96.9 97.6
P  .303 P  .133 P  .990
96.6 98.1 97.6
95.4 98.3 97.1
P  .276 P  .709 P  .546
S, great saphenous vein-single segment; SSV or ARM, small saphenous veinors o
P %
4.6
9.6
3.3
6.1
.013
5.2
4.5
1.7
5.7
.189
5.5
3.9
0.0
.007
7.4
4.4
.025
5.5
1.9
6.1
.033
3.9
5.3
2.5
.315
4.9
4.2
.607
GSV-Sgraft origin (P  .028) Table II.. The PP at 30 days for
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was 85.7%, compared with 93.2% for veins greater than 3.5
mm in diameter. For composite veins, the PP was 84.1%,
compared with 92.2% for SS GSV grafts. Bypasses that
originated from the CFA demonstrated 91.7% early PP,
those from the SFA 87.7%, and those from the popliteal
artery 93.9%.
Small diameter veins, composite graft type, and nonre-
versed bypasses all demonstrated higher rates of early graft
occlusion (loss of SP, Table II) on univariate analysis,
although the latter two factors were far less influential than
diameter. Of the technical variables analyzed, graft length,
distal anastomosis site, and the performance of a comple-
tion study had no significant effect on any of the primary or
secondary outcomes at 30 days. Early mortality and ampu-
tation were not impacted upon by any of the technical
factors analyzed.
Determinants of graft patency at 1 year. PP, PAP,
and SP at 1 year for the entire study population were 60.5%,
Fig 1. Outcomes at 1 year by the Kaplan-Meier met
(P  .0001). B, Primary assisted graft patency (P  .
salvage (P  .23).76.7%, and 80.1%, respectively. As demonstrated byKaplan-Meier method in Fig 1, the technical variable with
the greatest apparent influence on these outcomes was
graft diameter. Small diameter vein grafts (3.0 mm),
resulted in significantly inferior 1 year PP when com-
pared with large diameter vein grafts (3.5 mm) (42.4%
vs 68.4%, P .0001). This effect persisted on analysis of
PAP and SP (Table III).
Conduit type was strongly associated with PP, PAP,
and SP with composite grafts faring more poorly than
single segment arm veins or SSVs, which, in turn, per-
formed more poorly than GSVs (Fig 2, Table III). Longer
length grafts were associated with decreased 1 year PP only
(Fig 3, Table III). Grafts greater than 60 cm in length
resulted in a PP of 53.7%, compared with grafts less than 40
cm in length (PP of 69.0%, P  .0001). There was no
observable effect of graft length on PAP or SP.
Univariate analysis also demonstrated an association
between 1 year PP and the site of the proximal and distal
anastomoses. Grafts that originated from the CFA or SFA
based on conduit diameter. A, Primary graft patency
). C, Secondary graft patency (P  .0001). D, Limbhod
0001performedmore poorly than those from the popliteal artery
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grafts to a tibial artery underperformed grafts to a popliteal
artery, while a bypass to a pedal artery exhibited the most
robust PP (P  .024). Similar to the graft length variable,
the associations between anastomotic site and patency were
limited to the PP outcome only, with no observable effect
on PAP or SP at 1 year.
Multivariate Cox regression models that included all
technical variables found to be significant on univariate
analysis (graft diameter, graft type, graft length, proximal
and distal anastomoses), identified graft diameter, graft
type, graft length, and popliteal origin as robust indepen-
dent predictors of bypass primary patency rates (Table IV).
According to the magnitude of the hazard ratios (HR),
the strongest predictor for loss of PP, PAP, and SP was
clearly graft diameter (HRs for  3 mm diameter vein
2.35, 2.68, 2.90, respectively). The use of any non-SS
GSV bypass conduit was associated with a greater than
Table III. Univariate analysis of the effect of technical fac
bypass surgery
N PP % PA
All conduits 1404 60.5 7
Graft diameter
3 mm 77 42.4 5
3 to 3.5 mm 523 52.6 7
3.5 mm 701 68.4 8
P  .0001 P 
Graft length
40 cm 438 69.0 7
40 to 50 cm 345 62.0 7
50 to 60 cm 217 52.5 7
60 cm 353 53.7 7
P  .0001 P 
Graft type
GSV-SS 1086 64.4 7
SSV or ARM 66 51.5 7
Composite 201 42.4 6
P  .0001 P 
Orientation
Reversed 385 65.0 7
Nonreversed 701 63.3 7
P  .741 P 
Origin
CFA 665 57.1 7
SFA 334 60.5 7
Pop 229 74.2 8
P  .0001 P 
Distal
Pop 443 63.0 8
Tibial 719 57.9 7
Pedal 160 68.1 7
P  .024 P 
Completion study
Yes 788 63.0 7
No 616 58.1 7
P  .103 P 
PP, Primary patency; PAP, primary assisted patency; SP, secondary patency;
or arm vein; ANA, anastomosis.1.5 hazard ratio of loss of PP, PAP, and SP. Vein lengthpredicted 1 year loss of PP, with a hazard ratio of 1.50 for
grafts 50 to 60 cm and a hazard ratio of 1.33 for grafts
greater than 60 cm, compared with grafts  40 cm.
Similarly, graft origin had a significant association with
PP only. CFA and SFA origin grafts demonstrated infe-
rior 1-year PP when compared with popliteal artery
origin grafts; importantly, this effect persisted even after
controlling for vein graft length. Neither graft length nor
graft origin were important determinants of PAP or SP at
1 year. On multivariate analysis, no individual technical
variable had a significant impact on either limb salvage or
death at 1 year.
High-risk conduits. Perioperative (30-day) mortality
and major morbidity are displayed in Table V according to the
PREVENT III trial-specific conduit risk category. Reflecting
the broadly inclusive nature of the trial, high-risk grafts were
employed in 339 (24%) cases. Patients with a high-risk con-
duit experienced a 3.2% perioperative mortality, which was
on midterm (1 year) outcomes after lower extremity
SP % Limb salvage % Survival %
80.1 88.5 83.8
63.5 85.9 82.8
75.7 86.6 85.5
84.9 89.5 77.7
1 P  .0001 P  .232 P  .101
82.5 87.6 84.7
82.4 92.0 81.5
76.2 87.0 84.3
77.1 86.9 84.5
P  .142 P  .163 P  .576
82.5 89.5 83.1
72.1 80.9 83.8
69.3 85.4 87.3
1 P  .0001 P  .047 P  .305
82.5 88.4 83.0
82.5 91.5 83.3
P  .784 P  .091 P  .869
79.3 89.4 83.6
81.0 88.5 83.0
82.1 84.6 84.6
P  .744 P  .129 P  .879
83.8 93.7 84.5
77.9 85.6 83.4
80.1 86.8 84.5
P  .038 P  .001 P  .880
81.7 89.0 84.3
77.9 87.8 83.1
P  .072 P  .493 P  .539
S, great saphenous vein-single segment; SSV or ARM, small saphenous veintors
P %
6.7
7.7
3.0
1.7
.000
9.6
9.1
1.8
3.8
.072
9.5
2.1
2.9
.000
9.5
9.5
.789
5.8
7.2
0.0
.526
0.1
4.9
7.1
.100
7.4
5.8
.441
GSV-Snot significantly different from the 2.5%mortality rate seen in
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(7.4% vs 2.8%, P  .0001) and early amputation (3.3% vs
1.3%, P  .02) were more common among the high-risk
conduit group.
The primary study endpoints (PP, PAP, and SP) were
significantly inferior in the high- risk conduit group at both
30 days (85.8%, 90.7%, 92.6%) and at 1 year (44.2%, 63.7%,
69.0%). Use of such a conduit conferred a 2.1-fold in-
creased odds of 30 day graft failure (P  .0001) and a
2.3-fold increased odds of 1 year loss of SP (Fig 4). Al-
though the number of patients with tissue loss as the
indication for revascularization was no different between
conduit risk groups (P  .57), inferior early and midterm
limb salvage rates were seen in the high-risk group (odds
ratios for major amputation 2.5 and 1.6, respectively).
Patient survival in the two conduit risk groups was not
significantly different.
For the purpose of comparison, we also analyzed out-
comes for the subset of the non-high-risk group that had
optimal conduit characteristics (defined as SS GSV grafts
Fig 2. Outcomes at 1 year by the Kaplan-Meier m
(P  .0001). B, Primary assisted graft patency (P  .
salvage (P  .047).with a diameter greater than 3.5 mm). This “optimalconduit” group consisted of 604 bypasses (43% of study
population) performed, with an early (30 day) graft occlu-
sion rate of 1.7%. These grafts demonstrated PP of 71.5%,
PAP of 84.4%, and SP of 86.9% at 1 year. The 1-year limb
salvage rate and survival for this subset were 90.6% and
82.8%, respectively.
On resource utilization analysis (Table VI), the high-
risk conduit group was found to require a significantly
longer index LOS than the non-high-risk group (mean
9.37 days vs 8.71 days, P  .029). However, the cumula-
tive LOS, incorporating all admissions over 1 year post
surgery, was not different between groups. While the high-
risk conduits did require significantlymore graft reinterven-
tions over 1 year (mean 0.67 vs 0.42; P  .0001), the
number of overall rehospitalizations during the follow-up
period was not different.
DISCUSSION
Lower extremity bypass using autogenous vein, partic-
ularly in the context of limb salvage, is a technically de-
d based on conduit type. A, Primary graft patency
). C, Secondary graft patency (P  .0001). D, Limbetho
0001manding intervention whose results are benchmarked by
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gical judgment with regards to conduit selection and bypass
configuration are known to be of paramount importance
when performing IB for CLI. In many situations, these
technical factors may be at least partially under the control
of the operating surgeon. Therefore, gaining a clearer
understanding of how each of these factors contributes to
outcomesmay influence the way in which vascular surgeons
manage their critical limb ischemia patients.
PREVENT III, with its randomized cohort of 1404
Fig 3. Outcomes at 1 year by the Kaplan-Meier me
(P  .0001). B, Secondary patency (P  .16).
Table IV. Multivariate analysis identifying impact of pred
surgery
Covariate N
Loss of PP at 1 year
% failed Hazard ratio (95% CI) %
Graft diameter
3 mm 77 57.6 2.35* (1.71-3.23)
3 to 3.5 mm 523 47.4 1.56* (1.30-1.87)
3.5 mm 701 31.6 1.0 (ref)
Graft length
40 cm 438 31.0 1.0 (ref)
40 to 50 cm 345 38.0 1.26 (0.98-1.62)
50 to 60 cm 217 47.5 1.50* (1.14-1.99)
60 cm 353 46.3 1.33* (1.01-1.75)
Graft type
GSV-SS 1086 35.6 1.0 (ref)
Composite 201 57.6 1.47* (1.18-1.84)
SSV or ARM 66 48.5 1.59* (1.11-2.29)
Origin
CFA 665 42.9 1.0 (ref)
SFA 334 39.5 0.88 (0.71-1.10)
Pop 229 25.8 0.67† (0.47-0.95)
Distal
Pop 443 37.0 1.0 (ref)
Tibial 719 42.1 1.12 (0.90-1.40)
Pedal 160 31.9 0.98 (0.67-1.44)
PP, Primary patency; SP, secondary patency; GSV-SS, great saphenous vein-
*P value  .01 on multivariate analysis.
†P value  .05 on multivariate analysis.patients enrolled at more than 80 North American centers,provides a broad representation of the current practice of
autogenous vein IB for limb salvage. The study design
incorporated rigorous ultrasound surveillance and clini-
cal follow-up. As a result, this population provides an
excellent opportunity to study and compare the influ-
ence of multiple technical factors on the outcomes after
bypass surgery for CLI. Not surprisingly, vein diameter
and conduit type emerged from our analysis as the
primary technical determinants of early and midterm
graft failure. Longer graft length, inherently conferring a
based on conduit length. A, Primary graft patency
s on loss of patency at 1 year after lower extremity bypass
Loss of PAP at 1 year Loss of SP at 1 year
d Hazard ratio (95% CI) % failed Hazard ratio (95% CI)
2.69* (1.83-3.95) 36.5 2.91* (1.92-4.41)
1.40* (1.10-1.79) 24.3 1.55* (1.19-2.01)
1.0 (ref) 15.1 1.0 (ref)
1.0 (ref) 17.5 1.0 (ref)
1.04 (0.75-1.43) 17.6 0.95 (0.67-1.35)
1.37 (0.96-1.96) 23.8 1.22 (0.83-1.79)
1.13 (0.79-1.61) 22.9 1.04 (0.71-1.53)
1.0 (ref) 17.5 1.0 (ref)
1.53 (1.15-2.02) 30.7 1.41* (1.04-1.92)
1.55(0.96-2.51) 27.9 1.79* (1.10-2.91)
1.0 (ref) 20.7 1.0 (ref)
0.91 (0.68-1.21) 19.0 0.84 (0.63-1.17)
0.91 (0.59-1.39) 17.9 0.92 (0.58-1.44)
1.0 (ref) 16.2 1.0 (ref)
1.19 (0.88-1.60) 22.1 1.31 (0.95-1.81)
1.15 (0.71-1.85) 19.9 1.24 (0.74-2.07)
segment; SSV or ARM, small saphenous vein or arm vein.thodictor
faile
42.3
27.0
18.3
20.4
20.9
28.2
26.2
20.5
27.9
37.1
24.2
22.8
20.0
19.9
25.1
22.9
singlegreater number of potential failure points, was also an
e (P
SV, o
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predominate over arterial anatomy and graft orientation
on multivariate analysis.
These three main findings are consistent with several
smaller reports in the vascular literature. Towne and col-
leagues reported an analysis of conduit diameter in 239 infra-
Fig 4. Outcomes at 1 year by the Kaplan-Meier met
(diameter 3 mm or non-GSV). A, Primary graft patenc
C, Secondary graft patency (P  .0001). D, Limb salvag
Table V. Perioperative (30 day) mortality and morbidity b
Mortality
Morbidity
Myocardial Infarction
Stroke/TIA
Early graft occlusion
Major amputation
Any wound complication (documented by AE form) 1
*High-risk conduits (trial definition) included alternate veins (composite, Spopliteal GSV bypasses, showing a significant decrease incumulative patency for veins less than 3mm in diameter when
compared with larger veins, both at 1 month and at 1 year.4
Wengerter et al also demonstrated that veins less than 3 mm
had a significantly higher early graft failure rate, but found no
significant difference at 1 year.3 Similar to our findings, both
of these studies failed to show a significant difference with
based on trial-specific definition of high-risk conduits
.0001). B, Primary assisted graft patency (P .0001).
 .01).
al-specific risk category*
risk
%)
Non-high-risk
N (%) P value
Total
N (%)
.2) 26 (2.5) .42 37 (2.6)
.7) 44 (4.2) .27 63 (4.6)
.8) 14 (1.3) .54 20 (1.4)
.4) 29 (2.8) .0001 53 (3.9)
.3) 14 (1.3) .02 25 (1.8)
3.1) 397 (37.3) .06 543 (38.7)
r arm vein), or veins of diameter 3 mm.hod
y (Py tri
High-
N (
11 (3
19 (5
6 (1
24 (7
11 (3
46 (4regards to limb salvage or survival based on conduit diameter.
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the past, the use of autogenous veins other than GSV is an
appropriate strategy for limb salvage when adequate GSV is
not available. However, our current study confirms the
common theme carried through the previous reports: a
price must be paid in patency when utilizing these alterna-
tive vein conduits. Our results indicate that this price is a
significant increase in early graft failure, as well as a 1.8-fold
increase in the loss of SP at 1 year for SSV or arm vein bypass
grafts and a 1.4-fold increase in the loss of SP at 1 year for
composite vein grafts. Nonetheless, the cumulative patency
and limb salvage results at 1 year in this challenging group
of CLI patients remain quite respectable at 1 year, in
comparison to other options such as prosthetic.24-26
The effect of graft length on bypass outcomes has also
been explored, although not as rigorously as have other
technical variables. Wengerter and colleagues looked spe-
cifically at differences in patency among small diameter
grafts ( 3 mm) based on conduit length (45 cm vs 45
cm).4 Although that study had a much smaller population
and did not include a multivariate analysis to control for
potential confounders, they observed, in contrast to our
study, that the longer grafts had improved patency. One
trial randomized 160 patients undergoing IB who had
appropriate anatomy for distal origin grafts to either short
or long bypasses.12 The authors found no significant differ-
ence in patency, limb salvage, or survival between the two
groups at either 30 days or 1 year. Interestingly, similar to
our findings, Ballotta et al demonstrated a trend towards
improved PP (P .08) for shorter grafts at 5 years, but no
effect on any other outcomes analyzed.
In comparison to graft diameter and conduit type,
anastomotic choice and vein orientation had minimal ef-
fects on midterm outcomes. While nonreversed conduits
demonstrated a slight increase in early failures, the effect
size was very small and disappeared at 1 year. This finding
may possibly reflect some degree of technical error with
regards to valve lysis, but this is speculative. Nonetheless,
because the decrease in early patency was minimal and
previous large reports have shown no difference based on
orientation,20,27,28 we do not advocate one method over
the other. The influence of anastomotic site seen on uni-
variate analysis vanished on multivariate analysis, except in
the case of popliteal origin bypasses (improved PP). Aside
Table VI. Number of necessary reinterventions, rehospita
risk conduits including alternate veins (composite, SSV, or
Variable
All conduits,
n  1404 (mean)
H
n
Number of reinterventions 0.48
Number of rehospitalizations 1.48
Index LOS 8.87
Cumulative LOS 24.11
LOS, Length of stay.from shorter length grafts and fewer users of tobacco (bothcontrolled for in the model), it is unclear what specific
characteristics associated with a popliteal origin graft would
confer improved patency over CFA and SFA origin grafts.
Nonetheless, this finding is consistent with the robust
durability reported in numerous studies that have looked
specifically at distal origin grafts.12,14,15,29,30 We believe
these data support the judicious use of shorter length, distal
origin grafts where feasible.
In PREVENT III, the high-risk graft designation in-
corporated at least one and, in some cases, two of the most
significant predictors of poor durability (diameter 3 mm
or non-GSV). While the outcomes in this group were
significantly worse than the non-high-risk group, they were
still quite acceptable (SP 69%, LS 84.7% at 1 year). Accord-
ingly, use of a high-risk graft in the setting of CLI is an
appropriate strategy but may require a more aggressive
posture towards surveillance and reintervention. Surgeons
and patients alike should be aware of the critical importance
of close follow-up to maximize the long-term benefit of
these technically challenging operations. The 20% absolute
increment between PP and PAP in this subgroup is a clear
illustration of this concept. Thus, at a minimum, the duplex
surveillance protocol utilized in this study (1, 3, 6, and 12
months) should be adhered to. Whether such grafts would
benefit from adjunctive pharmacotherapy such as antico-
aguluation can not be addressed by this investigation. Fur-
ther efforts should be directed to improve the outcomes of
high-risk grafts. While a large randomized trial conducted
by Veith and colleagues24 demonstrated that prosthetic
bypasses for CLI (specifically in the infrapopliteal position)
had markedly inferior results when compared with autoge-
nous conduits, newer prosthetic technologies have recently
been developed with encouraging results in early studies
(ie, precuffed polytetrafluoroethylene [PTFE]26 and hepa-
rin bonded PTFE31). Nonetheless, it is difficult at this time
to definitively assess whether these improved prosthetic
alternatives will ultimately out perform high-risk autoge-
nous conduits; we anxiously await these evolving data.
In contrast to high-risk grafts, the analysis of optimal
bypass grafts (SS GSV with a diameter  3.5 mm) high-
lights, that when available in patients with CLI (43% of
cohort), these conduits are associated with excellent out-
comes (SP 86.9%, LS 90.6%, at 1 year). We believe these
ons, and cumulative length of stay over 1 year for high-
vein), or veins of diameter 3 mm
isk conduits,
39 (mean)
Non-high-risk conduits,
n  1065 (mean)
High-risk vs
Non-high-risk
(P value)
0.67 0.42 .0001
1.55 1.45 .163
9.37 8.71 .029
5.92 23.54 .112lizati
arm
igh-r
 3
2results confirm that autogenous vein bypass remains the
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which alternative procedures must be compared.
Several limitations inherent to this study are worthy of
mention. Because PREVENT III was not specifically de-
signed to assess the effect of technical variables on out-
comes, the methodology for recording technical variables
was not standardized and the technical variables available
for study were fixed. Specifically, the measurement of the
vein diameter at its narrowest point on distension and the
measurement of conduit length may have varied according
to the method chosen by the individual surgeon (ie, ruler,
caliper, etc.). In the design of the present study, we were
limited to those technical variables that were collected
during the original trial and unable to assess any additional
factors that had not been recorded (eg, method of harvest,
vein preparation solution, graft positioning, etc.). In situ
bypass grafts were excluded due to the ex vivo treatment
approach employed, so the results may not be directly
applicable to that technique. Furthermore, since all grafts in
the PREVENT study (both placebo and edifoligide
groups) were exposed to a ten minute incubation at 300
mm Hg of nondistending pressure,21 we cannot exclude
the possibility that handling of the grafts in this fashion
would influence the outcomes. Follow-up in the trial was
limited to 1 year by design. This Phase III study was
conducted at a large number of academic and nonacademic
centers, however, all were selected because of demon-
strated expertise and case volume of IB. Finally, even with
1404 patients in the cohort, there were not enough nega-
tive events at 30 days to be able to create an effective
multivariate model at that time point. As a result, 30-day
effects could only be analyzed with univariate techniques.
Accepting these limitations, this study represents the
largest analysis to look directly at the effects of technical
factors on lower extremity vein bypass surgery. Due to the
representative nature of the study cohort, we believe these
results to be generalizable to patients undergoing limb
salvage surgery in North America and are most relevant for
the design of future clinical trials in this area.
CONCLUSIONS
In this large cohort of patients undergoing autogenous
vein bypass grafts for limb salvage surgery at more than 80
institutions, vein diameter, conduit type, and graft length
emerged as the primary technical determinants of 30-day
and 1-year graft failure. As a result, when evaluating the
surgical options for bypass, whenever possible, we advocate
short length bypasses with large diameter (3.5 mm) GSV
conduit. Unfortunately, optimal conduits are often not
available in CLI patients (less than 50% of cases in the study
population). Ultimately, assessment of the anatomy re-
sponsible for the ischemia and of the available vein conduit
options, along with careful surgical judgment, dictates the
best revascularization strategy. Technical skill and postop-
erative diligence remain the cornerstones of clinical success
in the current surgical management of CLI.AUTHOR CONTRIBUTIONS
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Dr Jamal Hoballah (Iowa City, Iowa). I have some ques-
tions regarding the completion imaging. A few years ago, we
looked at factors that may affect the development of stenosis at the
distal anastomoses, and we found the presence of any technical
imperfections at the anastomotic site is a big predictor for devel-
opment of stenosis.
Your study seems to indicate that completion imagingmay not
be essential. Do you think the lack of importance of the completion
imaging in your study is a reflection of the technical expertise of the
surgeons who performed these procedures? With the current fel-
lows graduating with barely 25 to 50 vein grafts, can graduating
fellows skip completion angiograms?
Dr Andres Schanzer. In reference to your first question with
regards to the distal anastomosis and technical aspects at that site,
unfortunately with this data set, we only know if a completion
study was performed but do not have specific information on the
individual findings based on that angiogram or duplex.
In reference to your second question on the expertise of
performers, I think that this was the most broad representation of
infrainguinal bypass collected to date, including 83 community
and academic sites, so I think it is a fair representation of real world
practice.
As far as completion imaging, these data do not support it,
although I can tell you that duplex is easy to do and we do it
regularly on our vein bypasses.
Dr Kevin Burnand (London, United Kingdom). Thank
you very much for this nice study which confirms all previous
studies from centers. Can you tell me, a few technical things? Can
you tell me how your vein size and diameter was actually measured?
And I am assuming that you took the minimum diameter as the
one that you looked at. You have not told us anything about the
outflow from the leg and was that important in terms of patency.
And finally, the $64,000 question is, if you have a patient with
a less than 3.5 or less than 3 mm diameter vein, do you actually put
a PTFE bypass in, or do something different? You still seem to putDr Schanzer. In reference to your first question on how we
measured size and diameter, it was actually left to the discretion of
the surgeon with some specific requirements. For diameter, the
measurement was made at the smallest point on distention of the
vein. But as far as actually measuring it, whether using a ruler or a
caliper, it was left to the discretion of the surgeon, and the same
applies for length.
As far as the outflow, unfortunately, we do not actually have
outflow scores on these patients, so I am unable to comment on
that, although it certainly is an important point.
Your final question was about whether prosthetic is a better
option in the setting of a less than 3mmdiameter vein graft; we did
not compare vein with prosthetic in this study because no pros-
thetic bypasses were included in this cohort. I can tell you my
personal bias after studying these patients is that I think the results,
while worse than a greater than 3.5 mm diameter vein, are actually
still quite good and, I think, compare very favorably to all of the
prosthetic reviews that are available in the literature currently. So,
I do not think that a prosthetic is necessarily the ideal choice in that
situation.
Dr John Connolly (Orange, Calif). Do you think it is
important to control the pressure when expanding the vein to
locate branches for ligation? Otherwise one can traumatize the vein
lining. It has always beenmy opinion that one should control it and
I have believed that the relatively poorer long-term patency of vein
versus internal mammary artery when used for coronary bypass
could be explained by the trauma of very high pressures when one
is expanding the vein.
Dr Schanzer.With regards to controlling the pressure, we do
believe it is important. However, in this data set there was no
protocol-specific methodology for how the surgeons distended the
veins. All veins were distended for measurements. It is possible that
some high pressure distention was performed. We do try to main-
tain low pressures on distention and feel that your point is an
important one.
